Table 3.
Primary endpoints by domain at baseline and follow-up
| MSCs + CPCs | MSCs | CPCS | Placebo | ||
|---|---|---|---|---|---|
| LVEF (%) | |||||
| Baseline | [33] 29.21 (6.69) | [26] 29.26 (5.91 ) | [28] 26.31 (4.89) | [27] 29.66 (6.18) | |
| 6 months | [28] 29.29 (5.79) | [24] 29.43 (7.00) | [25] 27.21 (6.01) | [26] 29.18 (4.72) | |
| 12 months | [29] 29.91 (6.74) | [20] 31.12 (7.06) | [23] 26.96 (5.12) | [21] 29.35 (5.88) | |
| Global circumferential strain (%) | |||||
| Baseline | [26] −8.71 (2.50) | [17] −8.63 (3.23) | [22] −8.30 (2.88) | [16] −9.03 (3.73) | |
| 6 months | [26] −9.06 (3.34) | [17] −8.15 (2.57) | [22] −7.74 (2.96) | [16] −9.13 (2.29) | |
| 12 months | [26] −8.47 (2.78) | [17] −9.14 (3.12) | [22] −7.85 (2.54) | [16] −8.08 (3.46) | |
| Longitudinal strain (%) | |||||
| Baseline | [26] −10.18 (2.85) | [18] −10.00 (2.42) | [22] −9.47 (2.51) | [17] −9.58 (2.93) | |
| 6 months | [26] −10.68 (3.16) | [18] −10.51 (2.82) | [22] −10.22 (2.69) | [17] −10.49 (2.97) | |
| 12 months | [26] −10.13 (2.78) | [18] −10.77 (3.27) | [22] −9.92 (2.68) | [17] −10.32 (3.16) | |
| LVEDVI (mL/m2) | |||||
| Baseline | [33] 129.16 (32.44) | [26] 127.72 (34.36) | [28] 133.97 (27.75) | [27] 124.97 (29.83) | |
| 6 months | [28] 127.11 (30.36) | [24] 128.92 (33.69) | [25] 132.19 (22.20) | [26] 129.74 (29.76) | |
| 12 months | [29] 128.34 (33.74) | [20] 122.28 (34.15) | [23] 136.38 (26.22) | [21] 131.70 (28.26) | |
| LVESVI (mL/m2) | |||||
| Baseline | [33] 92.61 (29.71) | [26] 91.73 (30.89) | [28] 99.29 (24.30) | [27] 89.03 (27.25) | |
| 6 months | [28] 90.72 (26.45) | [24] 92.59 (31.04) | [25] 96.67 (20.35) | [26] 92.59 (25.57) | |
| 12 months | [29] 90.95 (29.45) | [20] 85.52 (30.57) | [23] 100.30 (24.39) | [21] 93.48 (23.74) | |
| Sphericity (mL) | |||||
| Baseline | [33] 0.56 (0.10) | [26] 0.56 (0.09) | [28] 0.57 (0.10) | [27] 0.55 (0.18) | |
| 6 months | [26] 0.58 (0.10) | [24] 0.55 (0.08) | [25] 0.58 (0.09) | [26] 0.57 (0.14) | |
| 12 months | [28] 0.58 (0.12) | [20] 0.54 (0.09) | [23] 0.59 (0.10) | [21] 0.55 (0.09) | |
| Scar size (%) | |||||
| Baseline | [28] 18.05 (7.01) | [23] 19.91 (5.86) | [27] 19.42 (4.73) | [27] 20.31 (5.50) | |
| 6 months | [23] 8.72 (6.62) | [21] 19.36 (6.55) | [23] 17.83 (4.94) | [22] 20.94 (5.01) | |
| 12 months | [23] 18.34 (6.27) | [17] 19.59 (5.79) | [20] 1.03 (6.17) | [18] 20.87 (5.42) | |
| Scar tissue mass (g) | |||||
| Baseline | [28] 30.54 (11.47) | [23] 30.42 (11.87) | [27] 32.81 (9.56) | [27] 33.20 (11.02) | |
| 6 months | [23] 31.78 (13.02) | [21] 29.60 (11.90) | [23] 30.04 (9.42) | [22] 34.64 (10.34) | |
| 12 months | [23] 32.09 (12.58) | [17] 29.69 (10.84) | [20] 32.29 (12.54) | [18] 33.61 (9.91) | |
| Peak VO2 (mL/kg/min) | |||||
| Baseline | [33] 16.37 (5.05) | [29] 17.39 (5.18) | [31] 15.62 (4.32) | [32] 15.60 (4.68) | |
| 6 months | [28] 15.74 (4.56) | [23] 16.84 (4.33) | [25] 16.57 (5.76) | [26] 16.55 (4.89) | |
| 12 months | [27] 15.78 (5.13) | [21] 18.02 (4.47) | [22] 16.28 (6.08) | [21] 16.54 (4.79) | |
| 6-min walk test (m) | |||||
| Baseline | [33] 366.11 (79.07) | [29] 369.34 (88.64) | [31] 378.81 (87.61) | [32] 367.50 (85.60) | |
| 6 months | [29] 390.31 (90.46) | [24] 390.75 (102.81) | [25] 379.88 (93.55) | [27] 376.78 (94.32) | |
| 12 months | [28] 397.07 (87.66) | [20] 400.38 (98.55) | [23] 391.65 (102.56) | [21] 384.88 (101.69) | |
| MLHFQ | |||||
| Baseline | [33] 43.72 (24.18) | [29] 46.59 (24.10) | [31] 29.47 (22.67) | [32] 39.00 (25.06) | |
| 6 months | [30] 25.54 (19.09) | [24] 29.93 (18.37) | [25] 21.69 (18.47) | [28] 34.25 (23.23) | |
| 12 months | [29] 25.35 (15.77) | [22] 30.02 (19.67) | [25] 25.68 (19.02) | [25] 36.55 (21.13) | |
| NT-proBNP (pg/mL) | |||||
| Baseline | [32] 1386.49 (4534.52) | [28] 665.65 (869.71 ) | [31] 801.78 (808.39) | [32] 856.72 (1364.72) | |
| 6 months | [30] 720.71 (851.24) | [24] 568.20 (592.43) | [25] 1084.04 (1070.04) | [27] 1388.43 (2356.32) | |
| 12 months | [29] 699.94 (755.80) | [21] 580.81 (756.89) | [23] 915.15 (757.94) | [23] 1072.32 (2161.64) |
Values are presented as [n] mean (standard deviation).
CPC, c-kit positive cardiac cell; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; MLHFQ, Minnesota Living with Heart Failure Questionnaire; MSC, mesenchymal stromal cell; NT-proBNP, N-terminal pro-brain natriuretic peptide; VO2, oxygen consumption.